KalVista Pharmaceuticals to Present Data at Upcoming Scientific Conferences
– Phase 1 Data on Oral Plasma Kallikrein Inhibitor KVD900 for Potential On-Demand Treatment of HAE Attacks to be Presented –
“We are excited to present more Phase 1 data on KVD900, our oral plasma
kallikrein inhibitor in development for on-demand treatment of
hereditary angioedema, or HAE,” said
C1 Inhibitor Workshop Presentations:
- KVD900, a new oral on-demand treatment of hereditary angioedema
attacks achieves complete plasma kallikrein suppression: safety,
tolerability, pharmacokinetic and pharmacodynamic results from a phase
1 first-in-human study
Saturday, May 25, 2019 from11:00-12:30 CEST , Oral 25
- High plasma exposures of KVD900 achieved in First in Human study
markedly inhibit plasma prekallikrein activation; early blockade of
plasma kallikrein (PKa) may halt attacks in hereditary angioedema
(HAE) by reducing contact system activation
Saturday, May 25, 2019 from2:30-4:00 pm CEST , Poster 35
EAACI Poster:
- Rapid and Nearly Complete Suppression of Plasma Kallikrein Activity
with the Oral Inhibitor KVD900: Results of a Phase 1 Study Evaluating
KVD900’s Potential as a Treatment for Acute Attacks of HAE
Tuesday, June 4, 2019 from10:30-12:00 pm WEST
PDS #21, Mediators in anaphylaxis and angioedema, Zone B
About
For more information, please visit www.kalvista.com.
Forward-Looking Statements
This press release contains
"forward-looking" statements within the meaning of the safe harbor
provisions of the U.S. Private Securities Litigation Reform Act of 1995.
Forward-looking statements can be identified by words such as:
"anticipate," "intend," "plan," "goal," "seek," "believe," "project,"
"estimate," "expect," "strategy," "future," "likely," "may," "should,"
"will" and similar references to future periods. These statements are
subject to numerous risks and uncertainties that could cause actual
results to differ materially from what we expect. Examples of
forward-looking statements include, among others, available funding, our
cash runway and future clinical trial timing and results. Further
information on potential risk factors that could affect our business and
its financial results are detailed in the annual report on Form 10-K
filed on
View source version on businesswire.com: https://www.businesswire.com/news/home/20190520005168/en/
Source:
KalVista Pharmaceuticals, Inc.
Leah Monteiro
Director,
Corporate Communications & Investor Relations
857-999-0808
leah.monteiro@kalvista.com